Leukemia patients see good results from Gleevec challengers

Drugs expected to help certain leukemia patients who saw relapses while taking Gleevec apparently are seeing cancer remission success rates in new clinical trials. About 86% of trial participants on Bristol-Myers Squibb's drug demonstrated a "hematologic" remission after up to nine months on the drug while Novartis, maker of Gleevec, has tested a successor that also has produced fewer side effects than the original.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ